EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC 4.0

Perampanel for the treatment of people with idiopathic generalized epilepsy in clinical practice

Eugen Trinka iD, Taoufik Alsaadi iD, Hiroko Goji, Taketoshi Maehara, Satoru Takahashi, Julia Jacobs, Rosaria Renna, Francisco José Gil-López, Rob McMurray, Ricardo Sáinz-Fuertes, Vicente Villanueva iD

Epilepsia · 2023

DOI: 10.1111/epi.17631 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Epilepsia, 2023. Verfasst von Eugen Trinka und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Christian-Doppler University Hospital, Paracelsus Medical University, Center for Cognitive Neuroscience, Member of EpiCARE, …. Hauptthemen laut MEDLINE: Epilepsies, Myoclonic, Epilepsy, Absence, Epilepsy, Generalized. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eisai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study was undertaken to evaluate perampanel (PER) when used under real‐world conditions to treat people with idiopathic generalized epilepsy (IGE) included in the PERaMpanel pooled analysIs of effecTiveness and tolerability (PERMIT) study.

Methods

The multinational, retrospective, pooled analysis PERMIT explored the use of PER in people with focal and generalized epilepsy treated in clinical practice across 17 countries. This subgroup analysis included PERMIT participants with IGE. Time points for retention and effectiveness measurements were 3, 6, and 12 months (last observation carried forward, defined as "last visit," was also applied to effectiveness). Effectiveness was evaluated by seizure type (total seizures, generalized tonic–clonic seizures [GTCS], myoclonic seizures, absence seizures) and included ≥50% responder rate and seizure freedom rate (defined as no seizures since at least the previous visit). Safety/tolerability was monitored throughout PER treatment and evaluated by documenting the incidence of adverse events (AEs), including psychiatric AEs and those leading to treatment discontinuation.

Results

The Full Analysis Set included 544 people with IGE (51.9% women, mean age = 33.3 years, mean epilepsy duration = 18.1 years). At 3, 6, and 12 months, 92.4%, 85.5%, and 77.3% of participants were retained on PER treatment, respectively (Retention Population, n = 497). At the last visit, responder and seizure freedom rates were, respectively, 74.2% and 54.6% (total seizures), 81.2% and 61.5% (GTCS), 85.7% and 66.0% (myoclonic seizures), and 90.5% and 81.0% (absence seizures) (Effectiveness Population, n = 467). AEs occurred in 42.9% of patients and included irritability (9.6%), dizziness/vertigo (9.2%), and somnolence (6.3%) (Tolerability Population, n = 520). Treatment discontinuation due to AEs was 12.4% over 12 months. Significance This subgroup analysis of the PERMIT study demonstrated the effectiveness and good tolerability of PER in people with IGE when administered under everyday clinical practice conditions. These findings are in line with clinical trial evidence, supporting PER's use as broad‐spectrum antiseizure medication for the treatment of IGE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epilepsies, MyoclonicEpilepsy, AbsenceEpilepsy, GeneralizedAdultFemaleHumansMaleAnticonvulsantsDrug Therapy, CombinationImmunoglobulin EPyridonesRetrospective StudiesSeizuresTreatment OutcomeNitriles

Stichwörter der Autor:innen

absence seizuresantiseizure medicationepilepsygeneralized tonic-clonic seizuresmyoclonic seizuresreal world

Substanzen

AnticonvulsantsImmunoglobulin EPyridonesperampanelNitriles

Autor:innen und Institutionen

  • Department of Neurology, Christian-Doppler University Hospital, Paracelsus Medical University, Center for Cognitive Neuroscience, Member of EpiCARE, Salzburg, Austria.
  • Neuroscience Institute, Christian-Doppler University Hospital, Paracelsus Medical University, Center for Cognitive Neuroscience, Salzburg, Austria.
  • Institute of Public Health, Medical Decision-Making, and HTA, UMIT-Private University for Health Sciences, Medical Informatics, and Technology, Hall in Tyrol, Austria.
  • Department of Neurology, American Center for Psychiatry and Neurology, Abu Dhabi, United Arab Emirates.
  • Neuropsychiatric Department, Aichi Medical University, Nagakute, Japan.
  • Department of Neurosurgery, Tokyo Medical and Dental University, Tokyo, Japan.

ORCID-Profile: Eugen Trinka, Taoufik Alsaadi, Vicente Villanueva

Förderung

  • Eisai

Zitieren

APA

Trinka, E., Alsaadi, T., Goji, H., Maehara, T., Takahashi, S., Jacobs, J., Renna, R., Gil-López, F. J., McMurray, R., Sáinz-Fuertes, R., & Villanueva, V. (2023). Perampanel for the treatment of people with idiopathic generalized epilepsy in clinical practice. Epilepsia. https://doi.org/10.1111/epi.17631

Vancouver

Trinka E, Alsaadi T, Goji H, Maehara T, Takahashi S, Jacobs J, et al. Perampanel for the treatment of people with idiopathic generalized epilepsy in clinical practice. Epilepsia. 2023. doi:10.1111/epi.17631

BibTeX
@article{Trinka2023,
  author = {Trinka, Eugen and Alsaadi, Taoufik and Goji, Hiroko and Maehara, Taketoshi and Takahashi, Satoru and Jacobs, Julia and Renna, Rosaria and Gil-López, Francisco José and McMurray, Rob and Sáinz-Fuertes, Ricardo and Villanueva, Vicente},
  title = {Perampanel for the treatment of people with idiopathic generalized epilepsy in clinical practice},
  journal = {Epilepsia},
  year = {2023},
  doi = {10.1111/epi.17631}
}
Kostenlos starten →